Sensei biotherapeutics to present preclinical data for sns-101, a conditionally active vista-blocking antibody, at the sixth annual cri-enci-aacr international cancer immunotherapy conference: translating science into survival

Boston, sept. 21, 2022 (globe newswire) -- sensei biotherapeutics, inc. (nasdaq: snse), an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer, today announced it will present additional preclinical data on sns-101, a monoclonal antibody targeting the immune checkpoint vista (v-domain ig suppressor of t cell activation), at the sixth annual cri-enci-aacr international cancer immunotherapy conference: translating science into survival, being held september 28 – october 1, 2022 at the new york hilton midtown in new york, new york.
SNSE Ratings Summary
SNSE Quant Ranking